EUCTR2006-006383-29-FR进行中（未招募）1 期
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the treatment of Post-Operative Ileus (POI)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects > 18 years of age.
- •2. Patients must meet the American Society of Anesthesiologists (ASA) physical status I, II, or III.
- •3. Subjects must be scheduled for a segmental colectomy via open laparotomy with general anesthesia. Acceptable procedures include: partial colectomy, colectomy (right or left), transverse colectomy, hemicolectomy (right or left), sigmoidectomy, cecectomy, anterior proctosigmoidectomy and low anterior proctosigmoidectomy. All patients must have a primary anastomosis.
- •4. Patients with a history of inflammatory bowel disease are eligible as long as the disease is not currently active and all other criteria are met.
- •5. Negative for history of chronic active hepatitis B, HCV or HIV infection.
- •6. Patients must sign an ICF.
- •7. Females of childbearing potential must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test prior to surgery and must use appropriate forms of birth control (oral, implantable or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device or (IUD), throughout the study.
- •8. Body weight within range of 40 kg to 150 kg (88 to 330 lbs.)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study if the meet any of the following exclusion criteria:
- •1. Patients who are scheduled for laparoscopic surgery for the segmental colectomy.
- •2. Patients with known hypersensitivity to methylnaltrexone, naltrexone, or naloxone.
- •3. Patients who received any investigational new drug (experimental) in the 30 days prior to screening visit.
- •4. Patients with clinical evidence of radiation enteritis.
- •5. Patients with recent history of treatment with Vinca alkaloids (< 6 months).
- •6. Patients with history of ulcerative colitis.
- •7. Patients undergoing operations resulting in gastrointestinal ostomies.
- •8. Patients with a significant medical and/or psychiatric history and co-morbidities that would make participation in an investigational study inappropriate or make them high-risk for any surgical procedures.
- •9. Patients with stage IV malignancies or ASA status IV are excluded.
- •10. Patients with a prior history of total colectomy, small bowel obstruction, known or suspected bowel adhesions (other than minor, clinically non-significant adhesions), or endometriosis of the bowel.
- •11. Patients who are anticipated to use post-operative non-steroidal anti-inflammatories (NSAIDs) prior to the primary endpoint being met.
- •12. Patients taking tricyclic antidepressants.
- •13. Patients with QTc interval greater than 500ms based on the 12-lead screening electrocardiogram (ECG).
- •14. Patients with a history of alcoholic or prescription or non-prescription drug abuse within the past two years.
- •15. Females who are pregnant or lactating.
- •16. Patients with calculated creatinine clearance (Cockcroft-Gault GRF) <50ml/min.
- •Pre-operative Period
- •Within 24 hours of the planned segmental colectomy, Investigators or designees will review inclusion/exclusion criteria, obtain vital sign measurements including body weight, review concomitant medications, obtain a urine pregnancy test (within 72 hours of dosing) for women of childbearing potential, clinical laboratory tests, and a 12-lead ECG recording. Patients who continue to meet all inclusion/exclusion criteria within 24 hours of surgery will be allowed to continue in the study. Patients who no longer qualify will be discontinued and managed at the discretion of the attending physician.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast CancerEUCTR2013-004525-84-PLCELLTRION, Inc.549
进行中（未招募）
1 期
A Phase 3 Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast CancerEUCTR2013-004525-84-ESCELLTRION, Inc.532
进行中（未招募）
不适用
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the treatment of Post-Operative Ileus (POI)EUCTR2006-006383-29-HUProgenics Pharmaceuticals, Inc.
进行中（未招募）
1 期
A Phase 3 Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast CancerHer-2 Positive Early Breast CancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004525-84-ITCELLTRION, Inc.549
进行中（未招募）
1 期
A Phase 3 Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast CancerHer-2 Positive Early Breast CancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004525-84-GRCELLTRION, Inc.549